Compare Citius Pharmaceuticals Inc (CTXR) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Fidelity National Information Servcs Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Fidelity National Information Servcs Inc trades at $41.21 (market cap $20.97B). The key difference: Fidelity National Information Servcs Inc is far larger — about 1432.4× Citius Pharmaceuticals Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.14% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | FIS | |
|---|---|---|
Market Cap | $14.64M | $20.97B |
Sector | Health | Technology |
52-Week High | $1.82 | $81.94 |
52-Week Low | $0.53 | $37.72 |
Enterprise Value | $10.86M | $41.37B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
FIS trades at $41.93, down 0.12% on the day, with a bullish technical signal from moving averages and strong institutional support. The stock shows attractive valuation metrics with a P/E of 8.13 and P/S of 1.91, while recent earnings have generally beaten expectations. Positive news flow highlights FIS's leadership in AI-driven banking technology and cloud infrastructure, with upcoming Q2 2026 earnings on August 4, 2026, providing a near-term catalyst.
The outlook for FIS is positive given its low valuation, analyst consensus price target of $52.57 (25% upside), and strategic focus on digital banking growth. Key risks include execution challenges post-Worldpay divestiture and rising debt levels, but strong cash flow generation and dividend yield of approximately 1.05% support shareholder returns. Institutional sentiment remains bullish with 58% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
